Safety, adherence and efficacy of PCSK9 inhibitors: a retrospective real-world study
Introduction PCSK9 inhibitors demonstrated their effectiveness in reducing low-density lipoprotein cholesterol (LDL-C) and cardiovascular events in landmark trials. It remains unclear whether the results can be translated to Asian populations. This study was designed to assess the real-world safety,...
Main Authors: | Bee Ling Kelly Chng, Wei Min Paul Heng, Yu Ming Soon, Jin Shing Hon, Yee How Lau, Ru San Tan, Jack Wei Chieh Tan |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2022-12-01
|
Series: | Proceedings of Singapore Healthcare |
Online Access: | https://doi.org/10.1177/20101058221144115 |
Similar Items
-
Association of PCSK9 Inhibitor Initiation on Statin Adherence and Discontinuation
by: Christopher LaFratte, et al.
Published: (2023-09-01) -
PCSK9 inhibitors
by: Baris Gencer, et al.
Published: (2015-04-01) -
The Impact of the COVID-19 Outbreak on Patients’ Adherence to PCSK9 Inhibitors Therapy
by: Valentina Maria Caso, et al.
Published: (2022-01-01) -
Safety of PCSK9 inhibitors
by: Grzegorz Grześk, et al.
Published: (2022-12-01) -
Eligibility, Clinical Outcomes, and Budget Impact of PCSK9 Inhibitor Adoption: The CANHEART PCSK9 Study
by: Dennis T. Ko, et al.
Published: (2018-11-01)